معرفی
Ragnhild Røysland serves as an Associate Professor at the University of Oslo's Faculty of Medicine within the Division of Diagnostics and Technology at Akershus University Hospital. Her work bridges clinical laboratory medicine and cardiovascular diagnostics, with primary focus on biomarker applications in acute dyspnea, heart failure, and pregnancy-related conditions through the Akershus Cardiac Examination (ACE) studies.
Her research centers on cardiovascular biomarkers including troponin, NT-proBNP, GDF-15, and osteoprotegerin, examining their diagnostic and prognostic utility across diverse clinical scenarios. Key interests include biomarker performance in acute dyspnea triage, pregnancy complications like preeclampsia and gestational diabetes, and pandemic-related conditions such as COVID-19. She investigates pre-analytical factors like blood sample stability and glycosylation effects on biomarker accuracy, with emphasis on translating laboratory findings to clinical decision-making.
Analysis of her 15 most recent publications reveals consistent focus on cardiovascular biomarker validation across acute and chronic conditions. Her work demonstrates particular strength in multi-center cohort studies (especially ACE series), biomarker kinetics in special populations (pregnant women, elderly), and comparative analyses of novel versus established markers. Recent trends show expanding applications in pandemic medicine and metabolic-cardiovascular interactions, with strong translational emphasis on improving diagnostic algorithms and risk stratification systems.
Dr. Røysland actively contributes to the Cardiovascular Research Group (CRG) at the University of Oslo, collaborating closely with clinicians at Akershus University Hospital to advance diagnostic protocols and evidence-based biomarker implementation in routine care.
